Phase 3 Tourette trial found no creatine relevance

Key Takeaways

• This JAMA Neurology trial tested ecopipam, not creatine.
• In paediatric responders, staying on ecopipam lowered relapse risk versus switching to placebo.
• The adult subgroup was very small, so adult results were inconclusive.
• Reported adverse events were mainly central nervous system effects such as somnolence, anxiety, headache, and insomnia.
• Nothing in this study changes standard creatine guidance, where monohydrate remains the most-studied form.

What the study actually found

The news here is about ecopipam, an investigational drug for Tourette syndrome, not about creatine. In this phase 3 randomized clinical trial, participants first entered a 12-week open-label ecopipam period. Those who responded were then randomized either to stay on ecopipam or taper to placebo for another 12 weeks.

The primary outcome was time to relapse in participants aged 6 to 18 years. Among paediatric participants who had already responded to treatment, ecopipam significantly reduced relapse risk compared with placebo, with a hazard ratio of 0.47 (95% CI, 0.26-0.84; P = .008). In plain English, children and teens who stayed on ecopipam were less likely to lose their earlier tic improvement during the double-blind phase.

In adults, the result pointed in the same direction numerically, with a hazard ratio of 0.51, but the confidence interval was wide and the result was not statistically significant. That adult finding is best treated as inconclusive rather than negative or positive.

The trial also reported that ecopipam was generally well tolerated over up to 24 weeks, with commonly reported adverse events including somnolence, anxiety, headache, insomnia, tic, and fatigue. Importantly, the authors reported no clinically meaningful impact on weight, metabolic parameters, or psychiatric scale measures, and no drug-induced movement disorders were observed.

For Creatine Canada readers, the key interpretive point is straightforward: this study does not test creatine, mention creatine as a treatment, or provide evidence that creatine helps or harms Tourette syndrome.

How the trial was designed and why that matters

This was a phase 3, double-blind, placebo-controlled, randomized withdrawal trial, conducted across 77 sites in 12 countries between January 2023 and February 2025. That design matters because it asks a specific question: once someone improves on ecopipam, does staying on the drug help preserve that benefit better than stopping it?

All 216 participants first received ecopipam in an open-label period, titrated over 3 to 4 weeks toward a target dose of 1.8 mg/kg per day. Only those who met the study’s responder definition, at least a 25% improvement in Yale Global Tic Severity Scale Total Tic Score at weeks 8 and 12, were randomized into the blinded maintenance phase.

That means the trial is strongest for answering a maintenance-of-effect question in responders. It is less suited to telling us how well ecopipam works for all-comers with Tourette syndrome in everyday care.

• Enrolled: 216 participants
• Paediatric participants: 167 of 216
• Randomized paediatric sample for primary analysis: 90
• Randomized adult sample: 14

The paediatric result is meaningful, but the randomized sample was still modest. The adult subgroup was especially small, which explains the wide confidence interval and uncertainty. As with many randomized withdrawal studies, enrichment for prior responders can make maintenance benefits easier to detect than in a broader population.

None of these limitations make the study unimportant. They just define what it can and cannot tell us.

What it means for people who take or are considering creatine

For creatine users, this paper is mostly a lesson in not overgeneralizing. Because the trial studied ecopipam rather than creatine, it should not change how you think about creatine’s benefits, safety profile, or appropriate use.

If you use creatine for strength training, sprint performance, or lean-mass support, the evidence base still rests on creatine-specific research, especially on creatine monohydrate. Broadly, mainstream guidance remains the same: monohydrate is the most-studied form; a common maintenance intake is 3 to 5 g/day; and those who want to saturate muscle stores faster sometimes use a loading protocol of about 20 g/day split into 4 doses for 5 to 7 days, followed by maintenance.

If you are trying to sort through practical options, our creatine guides cover the basics, and our creatine dosage calculator can help estimate a sensible daily amount. If you are comparing products, see our best creatine rankings, creatine brand reviews, and creatine product catalog.

Could creatine still matter to someone with Tourette syndrome? Possibly, but only in the generic sense that people with Tourette may also be athletes, lifters, or active adults who choose to use creatine for established sports-nutrition reasons. This specific paper gives no evidence that creatine treats tics, prevents relapse, interacts beneficially with ecopipam, or creates a new safety concern.

That distinction is crucial if you want evidence-based supplementation rather than condition-by-association.

How this fits with the wider evidence on creatine

The wider creatine literature is extensive, but it is focused mainly on exercise performance, muscle creatine storage, training adaptations, and general safety, not on Tourette syndrome. Reviews and position stands consistently conclude that creatine monohydrate is the best-studied form and is effective for increasing high-intensity exercise capacity and supporting gains in lean mass when paired with training.

For readers who want primary-context reading on creatine itself, the International Society of Sports Nutrition position stand remains a useful reference, and the review on common questions and misconceptions helps separate myth from evidence. Both are better guides to creatine than an unrelated Tourette drug trial. See Kreider et al. (2017) and Antonio et al. (2021).

That broader context matters because supplement conversations often drift from one neurological or psychiatric topic to another. But good evidence practice requires specificity:

• A drug trial does not automatically tell us anything about a supplement.
• A finding in Tourette syndrome does not automatically transfer to healthy athletes.
• Absence of creatine data in a paper is not evidence that creatine works or does not work for that condition.

So while this ecopipam trial is notable within Tourette research, it sits outside the evidence base that should guide creatine decisions.

Safety signals, limitations, and where readers can get confused

The most commonly reported adverse events with ecopipam across the open-label and double-blind periods were somnolence (11.1%), anxiety (9.7%), headache (9.7%), insomnia (8.8%), tic (7.9%), and fatigue (6.5%). These are central nervous system-type effects, which aligns with the drug’s mechanism as a selective dopamine D1 receptor antagonist.

Why mention them in a creatine article at all? Because readers often see a safety headline and assume it extends to supplements they already use. It does not. Creatine has a different mechanism, different evidence base, and different common discussion points. Within mainstream sports-nutrition evidence, creatine monohydrate is generally considered safe for healthy individuals when used as directed, although anyone with a medical condition, taking medications, or managing a neurological disorder should discuss supplementation with a qualified clinician.

This study also has interpretive limits:

1. It was enriched for prior responders, so it does not answer every efficacy question.
2. The adult subgroup was too small for firm conclusions.
3. The follow-up was up to 24 weeks, which is useful but not definitive for long-term treatment.
4. It did not compare ecopipam against other Tourette medications.

The biggest possible reader error would be to turn a carefully run Tourette drug trial into a creatine story. The accurate take is narrower: an ecopipam maintenance signal in paediatric responders, with tolerability that looks reasonably encouraging over the study window.

Bottom line for creatine readers

This study is important for Tourette syndrome research, not for creatine science. In children and adolescents with Tourette syndrome who first improved on ecopipam, continuing the drug reduced relapse risk versus tapering to placebo over the 12-week double-blind phase. Adults were too few to draw confident conclusions.

For people who use creatine, nothing here changes current best practice. If your goal is better training performance or support for strength and lean mass, rely on the established creatine literature rather than borrowing conclusions from unrelated drug trials. Monohydrate remains the default evidence-based choice, standard maintenance remains 3 to 5 g/day for many users, and product selection should still come down to quality, transparency, and price per effective dose.

If you have Tourette syndrome or another neurological condition and also use creatine, the sensible move is not to assume benefit or risk from this paper. Instead, keep the two questions separate: what does the evidence say about your medical treatment, and what does the evidence say about your supplement use?

That is the cleanest reading of the paper and the most trustworthy answer to what it means for creatine: essentially nothing direct, but a useful reminder to stay evidence-specific.

What this trial showed and what it did not

• 216 participants enrolled — Entered the open-label ecopipam phase
• 0.47 paediatric relapse hazard ratio — Ecopipam vs placebo in randomized responders
• 24 weeks maximum treatment window — 12 weeks open-label plus 12 weeks double-blind
• 3-5 g/day typical creatine maintenance intake — Mainstream guidance for creatine monohydrate, not from this Tourette trial

Frequently Asked Questions

Sources & Further Reading

• Kreider et al. (2017), ISSN Position Stand: Safety and Efficacy of Creatine — JISSN
• Antonio et al. (2021), Common questions and misconceptions about creatine supplementation — JISSN